ClinicalTrials.gg
RecruitingNCT06421181KEM-HENUpdated Jan 15, 2025

Hemodynamic Effects of Anesthesia Induction

An observational study in Patients Undergoing Anaesthesia Induction, sponsored by Kliniken Essen-Mitte. Recruiting at 1 site in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-15.

Sponsored by Kliniken Essen-Mitte · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
Female
01

Study summary

The idea of that project is to characterize the hemodynamic changes of a daily used clinical intervention (induction of anesthesia) in a highly controlled environment by two hemodynamic monitoring devices. The aim is an advanced hemodynamic profiling of this intervention and additionally screen for changes in flow patterns in an exploratory fashion.

Both devices complement one another in their hemodynamic profiling ability. One device is a continuous monitoring with instant traceable changes and the other an intermittent point-of-care ultrasound/echocardiography device with advanced possibilities for differential diagnostics.

A second purpose is to test the possibility to implement advanced echocardiography in a point-of-care approach during anaesthesia induction and evaluate the time and quality of a comprehensive analysis by a not-certified anaesthetists with an echocardiography device with features of artificial intelligence versus a certified expert.

Read the detailed description

Mortality after surgery is still high and high-risk procedures are associated to high postoperative complication rates. For hemodynamic monitoring, a meta-analysis showed a reduction in mortality and especially for the esophageal Doppler a reduction in postoperative complications. However, the effects reducing mortality and morbidity have to be considered as low. Probably, this is the reason why daily clinical implementation rates of hemodynamic monitoring are low, too.

However, hemodynamic studies only focus on intraoperative optimization, but recent publications suggested that taking preoperative individual hemodynamic values for arterial blood pressure and cardiac index as targets for optimization provides advanced therapeutic options. Lastly, both studies do not provide data about the preoperative values and their changes during the induction of anesthesia.

Our own data confirm that the induction of anesthesia, the establishment of a working epidural and the surgical incision of the abdomen leads to decreased cardiac index and markers of inotropy in otherwise cardiovascular healthy patients. However, the intervention studies and our own data strongly suggest that starting hemodynamic monitoring after the induction of anesthesia or the surgical incision may foreclose that the clinician can guide the hemodynamic therapy towards individualized goals. Additionally, the corrective treatment in this scenario could be different from just vasopressors.

Nevertheless, in contrast to our own data a recent study showed that hypotension in the post-induction period is primarily associated with a decreased vascular tone due to anesthetic agents, suggesting that the appropriate treatment is vasopressors.

A detailed hemodynamic profiling of non-cardiac patients undergoing high-risk cancer surgery prior, during and after the induction of anaesthesia may provide new insights about the effects of anaesthetic drugs, positive pressure ventilation, and changes of sympathetic tone.

02

Conditions studied

  • Patients Undergoing Anaesthesia Induction

Keywords

  • Hemodynamic monitoring
  • Point-of-care ultrasound
  • Point-of-care echocardiography
  • Anaesthesia induction
  • Respiratory effects
03

In context

Lead sponsor

Kliniken Essen-Mitte is the lead sponsor of 18 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with the diagnosis of advanced primary ovarian cancer will be screened prior to cytoreductive surgery in cooperation with the colleagues of gynaecological oncology. If the patients are eligible they will be informed to give consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing elective laparotomy in the hospital Evangelische Kliniken Essen-Mitte
  • Due to the invasiveness of the planned surgery there is an indication for an arterial and central-venous line as well as an peridural catheter

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Lack of written
  • Insufficient language skills
  • Unwillingness to have pseudonymized disease data stored at the study site and lack of consent to share anonymized data as part of the clinical trial
  • American society of anaesthesiologists physical status higher as grade 3
  • congestive heart failure with a grade of 2 or higher according to the (NYHA)
  • Ischemic cardiopathy with a grade of 2 or higher according to the Canadian cardiovascular society (CCS)
  • Known severe valve pathologies of the heart
  • Chronic kidney disease with dependency of hemodialysis
  • Atrial fibrillation ora trail flutter
  • Pulmonary hypertension
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Longitudinal change of heart rate assessed in percentages during the induction of anaesthesia

    The heart rate will be monitored continuously to detect any change of it during the induction of anaesthesia. The change will be described in percentages.

    Time frame: Time from the start of anaesthesiological monitoring up to start of surgical measures, up to four hours

  2. Longitudinal change of arterial blood pressure assessed in percentaqes during the induction of anaesthesia

    The arterial blood pressures will be monitored continuously to detect any change of it during the induction of anaesthesia. The change will be described in percentages.

    Time frame: Time from the start of anaesthesiological monitoring up to start of surgical measures, up to four hours

  3. Longitudinal change of stroke volume assessed in percentaqes during the induction of anaesthesia

    The stroke volume will be monitored continuously to detect any change of it during the induction of anaesthesia. The change will be described in percentages.

    Time frame: Time from the start of anaesthesiological monitoring up to start of surgical measures, up to four hours

  4. Longitudinal change of myocardial strain imaging assessed by transthoracic echocardiography during the induction of anaesthesia

    The echocardiographic feature of strain imaging for the analysis of contractile performance of the myocardium will be monitored prior to induction and after induction of anaesthesia to detect any changes

    Time frame: Time from the start of anaesthesiological monitoring up to start of surgical measures, up to four hours

Secondary outcomes

  1. Changes in percentages in a comprehensive echocardiographic assessment of the right ventricle and atrium

    The echocardiographic features will be monitored prior to induction and after induction of anaesthesia to detect any changes

    Time frame: Time from the start of anaesthesiological monitoring up to start of surgical measures, up to four hours

  2. Changes of the left ventricular and atrial volume in percentages assessed by a transthoracic echocardiography

    The echocardiographic parameter will be monitored prior to induction and after induction of anaesthesia to detect any changes.

    Time frame: Time from the start of anaesthesiological monitoring up to start of surgical measures, up to four hours

  3. Changes of the left ventricular systolic and diastolic function in percentages assessed by a transthoracic echocardiography

    The echocardiographic features will be monitored prior to induction and after induction of anaesthesia to detect any changes

    Time frame: Time from the start of anaesthesiological monitoring up to start of surgical measures, up to four hours

  4. Changes of function of the cardiac valves assessed by a transthoracic echocardiography

    The echocardiographic features will be monitored prior to induction and after induction of anaesthesia to detect any changes of the cardiac valve functions like increase of regurgitation

    Time frame: Time from the start of anaesthesiological monitoring up to start of surgical measures, up to four hours

  5. Changes in percentage of the cardiocirculatory flow in an advanced hemodynamic monitoring device based on a pulse-contour methodology in a continuous fashion during induction of anaesthesia

    The haemodynamic features will be monitored prior to the start of induction up to the end of induction of anaesthesia to detect any changes

    Time frame: Time from the start of anaesthesiological monitoring up to start of surgical measures, up to four hours

  6. Changes of flow profiles of the splanchnic vessels as well as peripheral arteries determined by ultrasound

    The ultrasound features will be monitored prior to induction and after induction of anaesthesia to detect any changes

    Time frame: Time from the start of anaesthesiological monitoring up to start of surgical measures, up to four hours

  7. Mean systemic filling pressure (MSFP)

    The MSFP will be determined based on the stop-flow-methodology to determine additionally venous return characteristics

    Time frame: Time from the start of anaesthesiological monitoring up to start of surgical measures, up to four hours

  8. Baroreceptor sensitivity (BRS)

    BRS will be determined to analyse the impact of drugs of anaesthesia induction on the vegetative nervous system. The assessment is based on invasive measurement of the arterial blood pressure in combination with the electrocardiogram

    Time frame: Time from the start of anaesthesiological monitoring up to start of surgical measures, up to four hours

Other outcomes

  1. Examination times of the echocardiographic assessment by a not-certified expert

    The characteristics of an echocardiographic assessment will be analysed to examine the feasibility within clinical routine and the results will be compared to the results of a certified echocardiographic expert

    Time frame: Time from the start of anaesthesiological monitoring up to the start of anaesthesia induction, up to four hours

  2. Implementation rates in percentages of the echocardiographic assessment by a not-certified expert during clinical care

    The characteristics of an echocardiographic assessment will be analysed to examine the feasibility within clinical routine and the results will be compared to the results of a certified echocardiographic expert

    Time frame: Time from the start of anaesthesiological monitoring up to the start of anaesthesia induction, up to four hours

  3. Number of missed diagnositics of the echocardiographic assessment by a not-certified expert vs. an assessment by a certified examiner

    The characteristics of an echocardiographic assessment will be analysed to examine the feasibility within clinical routine and the results will be compared to the results of a certified echocardiographic expert

    Time frame: Time from the start of anaesthesiological monitoring up to the start of anaesthesia induction, up to four hours

  4. Incidence and description of postoperative complications

    The complications will be graded according to the "Clavien-Dindo" classification from one to five with one being a minor complication and five being death

    Time frame: Time of hospital stay, i.d. from the time of surgery up to discharge from the hospital, up to 30 days after surgery

  5. Incidence and description of postoperative organ dysfunctions

    The incidence of organ dysfunctions will be based on laboratory results and or pathophysiological features like delayed bowel opening after surgery

    Time frame: Time of hospital stay, i.d. from the time of surgery up to discharge from the hospital, up to 30 days after surgery

07

Study locations

1 of 1 sites recruiting
  • Evangelische Kliniken Essen-Mitte
    Essen, NRW 45136, Germany
    Recruiting
08

References and documents

Publications

  • Chong MA, Wang Y, Berbenetz NM, McConachie I. Does goal-directed haemodynamic and fluid therapy improve peri-operative outcomes?: A systematic review and meta-analysis. Eur J Anaesthesiol. 2018 Jul;35(7):469-483. doi: 10.1097/EJA.0000000000000778. PubMed 29369117 ↗
  • Ripolles-Melchor J, Casans-Frances R, Espinosa A, Abad-Gurumeta A, Feldheiser A, Lopez-Timoneda F, Calvo-Vecino JM; EAR Group, Evidence Anesthesia Review Group. Goal directed hemodynamic therapy based in esophageal Doppler flow parameters: A systematic review, meta-analysis and trial sequential analysis. Rev Esp Anestesiol Reanim. 2016 Aug-Sep;63(7):384-405. doi: 10.1016/j.redar.2015.07.009. Epub 2016 Feb 10. English, Spanish. PubMed 26873025 ↗
  • Sessler DI, Bloomstone JA, Aronson S, Berry C, Gan TJ, Kellum JA, Plumb J, Mythen MG, Grocott MPW, Edwards MR, Miller TE; Perioperative Quality Initiative-3 workgroup; POQI chairs; Miller TE, Mythen MG, Grocott MP, Edwards MR; Physiology group; Preoperative blood pressure group; Intraoperative blood pressure group; Postoperative blood pressure group. Perioperative Quality Initiative consensus statement on intraoperative blood pressure, risk and outcomes for elective surgery. Br J Anaesth. 2019 May;122(5):563-574. doi: 10.1016/j.bja.2019.01.013. Epub 2019 Feb 27. PubMed 30916004 ↗
  • Kouz K, Wegge M, Flick M, Bergholz A, Moll-Khosrawi P, Nitzschke R, Trepte CJC, Krause L, Sessler DI, Zollner C, Saugel B. Continuous intra-arterial versus intermittent oscillometric arterial pressure monitoring and hypotension during induction of anaesthesia: the AWAKE randomised trial. Br J Anaesth. 2022 Oct;129(4):478-486. doi: 10.1016/j.bja.2022.06.027. Epub 2022 Aug 23. PubMed 36008202 ↗
  • Futier E, Lefrant JY, Guinot PG, Godet T, Lorne E, Cuvillon P, Bertran S, Leone M, Pastene B, Piriou V, Molliex S, Albanese J, Julia JM, Tavernier B, Imhoff E, Bazin JE, Constantin JM, Pereira B, Jaber S; INPRESS Study Group. Effect of Individualized vs Standard Blood Pressure Management Strategies on Postoperative Organ Dysfunction Among High-Risk Patients Undergoing Major Surgery: A Randomized Clinical Trial. JAMA. 2017 Oct 10;318(14):1346-1357. doi: 10.1001/jama.2017.14172. PubMed 28973220 ↗
  • Nicklas JY, Diener O, Leistenschneider M, Sellhorn C, Schon G, Winkler M, Daum G, Schwedhelm E, Schroder J, Fisch M, Schmalfeldt B, Izbicki JR, Bauer M, Coldewey SM, Reuter DA, Saugel B. Personalised haemodynamic management targeting baseline cardiac index in high-risk patients undergoing major abdominal surgery: a randomised single-centre clinical trial. Br J Anaesth. 2020 Aug;125(2):122-132. doi: 10.1016/j.bja.2020.04.094. PubMed 32711724 ↗
  • Saugel B, Bebert EJ, Briesenick L, Hoppe P, Greiwe G, Yang D, Ma C, Mascha EJ, Sessler DI, Rogge DE. Mechanisms contributing to hypotension after anesthetic induction with sufentanil, propofol, and rocuronium: a prospective observational study. J Clin Monit Comput. 2022 Apr;36(2):341-347. doi: 10.1007/s10877-021-00653-9. Epub 2021 Feb 1. PubMed 33523352 ↗
  • Middel C, Stetzuhn M, Sander N, Kalkbrenner B, Tigges T, Pielmus AG, Spies C, Pietzner K, Klum M, von Haefen C, Hunsicker O, Sehouli J, Konietschke F, Feldheiser A. Perioperative advanced haemodynamic monitoring of patients undergoing multivisceral debulking surgery: an observational pilot study. Intensive Care Med Exp. 2023 Sep 8;11(1):61. doi: 10.1186/s40635-023-00543-1. PubMed 37682496 ↗
  • Feldheiser A, Juhl-Olsen P, Nordine M, Stetzuhn M, Wiegank L, Knebel F, Treskatsch S, Berger C. A comprehensive echocardiographic analysis during simulated hypovolaemia: An observational study. Eur J Anaesthesiol. 2023 Aug 1;40(8):578-586. doi: 10.1097/EJA.0000000000001863. Epub 2023 Jun 1. PubMed 37265333 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Dec 2025, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2024
First posted
May 20, 2024
StartActual
Jan 14, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jun 30, 2026
Last update
Jan 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06421181
Lead sponsor
Kliniken Essen-Mitte
Responsible party
Sponsor
First posted
May 20, 2024
Start date
Jan 14, 2025
Primary completion
Dec 31, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Jan 15, 2025

Study contacts

Aarne Feldheiser, M.D., PhD.
Contact
a.feldheiser@kem-med.com
+49201174 ext. 31001
Stefan Boland
Contact
s.boland@kem-med.com
+49201174 ext. 31001
Aarne Feldheiser, M.D., PhD.
principal investigator · Evangelische Kliniken Essen-Mitte

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion